ALSO NOTED: Emisphere shares dive on Phase II data; NovImmune raises $46M;and much more...

> Shares of Emisphere Technologies took a nasty hit today after the company reported negative Phase II data from a diabetes study. Report

> Switzerland's NovImmune raised $46 million in its second round of financing. Release

> AAIPharma has raised $30 million through a rights offering to existing shareholders. Release

> Shares in Germany's Paion surged today after an independent committee recommended that it resume enrolling patients for a trial of its stroke drug desmoteplase. Report

> In the event of a Democratic takeover of the House next week, start looking for high-profile hearings on the pharmaceutical industry's "profiteering" ways. Report

> GlaxoSmithKline said today that a review of its data indicates that Cervarix can reduce the incidence of cervical cancer by up to 80 percent. Report

> In the 1930s scientists discovered that restricting calorie intake by a third could extend life spans by 30 to 40 percent. Now a number of biotechs are involved in efforts to recreate the effects of a restricted calorie diet in pill form. Report

And Finally… College grads in the U.S. appear to be increasingly unqualified for jobs in biotechnology. Article

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.